Cathie Wood's ARK ETFs shift focus, buying NVIDIA and selling GUARDANT

Cathie Wood's ARK ETFs executed significant portfolio adjustments on July 22, 2025, strategically increasing exposure to genomics and artificial intelligence. ARKG notably purchased 31,265 shares of Illumina Inc. and ARKX added 11,973 shares of NVIDIA Corp., signaling continued bullishness on these high-growth sectors. Concurrently, ARK divested from precision oncology and aerospace, with ARKG selling 68,228 shares of Guardant Health Inc. and ARKX offloading 43,481 shares of Rocket Lab USA Inc., reflecting a tactical rebalancing to align with broader investment theses.

Analysis

ARK Invest's daily trading activity on July 22, 2025, demonstrates a clear strategic concentration of capital into high-conviction themes, particularly artificial intelligence and genomics. The ARKG ETF's purchase of 31,265 shares in Illumina (ILMN) for approximately $2.98 million and the ARKX ETF's addition of 11,973 NVIDIA (NVDA) shares valued at $2.05 million underscore a continued bullish thesis on these sector leaders. The consistent accumulation of NVIDIA, as noted in the report, signals strong confidence in the company's long-term growth trajectory. Conversely, ARK executed patterned divestments, indicating a tactical rebalancing. The sale of 68,228 Guardant Health (GH) shares by ARKG for over $3.11 million and the offloading of 43,481 Rocket Lab (RKLB) shares by ARKX for $2.05 million represent a continued reduction of exposure to these specific names. This suggests a potential strategic reallocation of capital or a revised assessment of the near-term outlook for the precision oncology and commercial space industries.

Key Decisions for Investors

• Investors should view ARK's consistent accumulation in NVIDIA (NVDA) and significant buy into Illumina (ILMN) as a strong reaffirmation of a long-term bullish outlook for the AI and genomics sectors.
• Holders of Guardant Health (GH) and Rocket Lab (RKLB) should note the continued, patterned selling by ARK, which may warrant a re-evaluation of these positions given the fund's apparent strategic shift away from them.
• The trades signal a clear capital rotation, and investors could consider if their own portfolios reflect a similar conviction in core technology leaders over more speculative or niche growth areas.
• Followers of ARK's strategy should interpret these moves as active management decisions to concentrate capital, rather than a broad market call, and should conduct their own due diligence on the underlying fundamentals of the divested companies.